Header Logo

Connection

Wendy Stevens to Africa South of the Sahara

Back to Details
This is a "connection" page, showing publications Wendy Stevens has written about Africa South of the Sahara.
Wendy Stevens
Connection Strength
0,432
Africa South of the Sahara
  1. HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018. MMWR Morb Mortal Wkly Rep. 2021 May 28; 70(21):775-778.
    View in: PubMed
    Score: 0,042
  2. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020 08 01; 34(10):1559-1566.
    View in: PubMed
    Score: 0,040
  3. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS. 2018 05 15; 32(8):1043-1051.
    View in: PubMed
    Score: 0,034
  4. Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016. MMWR Morb Mortal Wkly Rep. 2016 Dec 02; 65(47):1332-1335.
    View in: PubMed
    Score: 0,031
  5. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016 Nov; 16(11):e267-e275.
    View in: PubMed
    Score: 0,031
  6. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 09 15; 214(6):873-83.
    View in: PubMed
    Score: 0,030
  7. Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries. MMWR Morb Mortal Wkly Rep. 2015 Nov 27; 64(46):1287-90.
    View in: PubMed
    Score: 0,029
  8. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS. 2012 Aug 24; 26(13):1663-72.
    View in: PubMed
    Score: 0,023
  9. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
    View in: PubMed
    Score: 0,023
  10. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012 May; 54 Suppl 4:S294-9.
    View in: PubMed
    Score: 0,023
  11. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012 Jun; 54(11):1660-9.
    View in: PubMed
    Score: 0,023
  12. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44.
    View in: PubMed
    Score: 0,022
  13. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012 Apr; 12(4):307-17.
    View in: PubMed
    Score: 0,022
  14. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
    View in: PubMed
    Score: 0,021
  15. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb; 41(1):43-54.
    View in: PubMed
    Score: 0,020
  16. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008; 13(5):625-39.
    View in: PubMed
    Score: 0,017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.